Virginia Oncology Associates

Chesapeake, Virginia 23320

4 studies enrolling now · 15 studies all time

What they study most

Breast Cancer, Breast Neoplasms, Castration-Resistant Prostate Cancer, Early Breast Cancer, Esophageal Adenocarcinoma, Follicular Lymphoma, Gastroesophageal Junction Cancer, Kidney Neoplasms, Melanoma, Metastatic Breast Cancer, Metastatic Gastric Cancer, Non-small Cell Lung Cancer

Studies at this site

• Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer — Recruiting now
• Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer — Recruiting now
• A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment. — Recruiting now
• A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer — Recruiting now
• Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors — Completed
• A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression — Completed
• Breast Cancer Index (BCI) Registry — Running, not enrolling
• Avelumab and Talazoparib in Untreated Advanced Ovarian Cancer (JAVELIN OVARIAN PARP 100) — Stopped early
• Trial of Sacituzumab Govitecan in Participants With Refractory/Relapsed Metastatic Triple-Negative Breast Cancer (TNBC) — Completed
• Talazoparib For Neoadjuvant Treatment Of Germline BRCA1/2 Mutation Patients With Early Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer — Stopped early
• Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer — Completed
• Safety and Efficacy Study of MDV3100 in Patients With Castration-Resistant Prostate Cancer Who Have Been Previously Treated With Docetaxel-based Chemotherapy — Completed
• Elesclomol (STA-4783) With Paclitaxel Versus Paclitaxel Alone in Melanoma — Stopped early
• Triple Negative Breast Cancer Biomarker Study — Completed
• Safety & Efficacy Study of AT-101 in Combination w/ Rituximab in Previously Untreated Grade I-II Follicular Non-Hodgkin's Lymphoma — Completed